<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hartono Kahar</style></author><author><style face="normal" font="default" size="100%">Sari Prabandari Prasetyaningrum</style></author><author><style face="normal" font="default" size="100%">Munawaroh Fitriah</style></author><author><style face="normal" font="default" size="100%">Aryati</style></author><author><style face="normal" font="default" size="100%">Jusak Nugraha</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Analysis of Covid-19 Neutralizing Antibody Levels Post Vaccination using Ichroma™ and iFlash Covid-19 Nab</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Ichroma</style></keyword><keyword><style  face="normal" font="default" size="100%">iFlash.</style></keyword><keyword><style  face="normal" font="default" size="100%">Neutralizing Antibody</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">March 2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">15</style></volume><pages><style face="normal" font="default" size="100%">171-174</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background:&lt;/strong&gt; One of the efforts to control SARS-CoV-2 infection in health workers is vaccination. In this study, the levels of SARS-CoV-2 neutralizing antibody (nAb) in health workers were measured with Ichroma and iFlash. &lt;strong&gt;Methods:&lt;/strong&gt; This study applied an observational analytic design with a prospective cohort and was conducted at Dr. Soetomo Regional Public Hospital, Surabaya, from January to November 2021. The population of this study included a total of 75 health workers after taking the second dose of the SARS-CoV-2 (Sinovac) vaccine. The Covid-19 NAb levels of the population were tested with Ichroma and iFlash on day 0 before vaccination, as well as days 14 and 28, and months 3 and 6 after vaccination. &lt;strong&gt;Results: &lt;/strong&gt;The Friedman test indicated a significant difference in NAb levels according to the iFlash test on day 14, day 28, month 3, and month 6 compared to those before vaccination (p &amp;lt; 0.05). The Wilcoxon test revealed a significant difference in NAb levels on day 14, day 28, month 3, and month 6. The results of the Cochran test showed a significant difference in the positivity of NAb according to the Ichroma test on day 14, day 28, month 3, and month 6 compared to those before vaccination (p &amp;lt; 0.05). McNemar's test demonstrated that the COI at month 3 was not significantly different from that before vaccination; The COI at month 6 was not significantly different from those at days 14 and 28. The results of the Pearson correlation test and Bland–Altman plot indicated a moderate correlation between Ichroma and iFlash (r = 0.592, p = 0.002).&lt;strong&gt; Conclusion:&lt;/strong&gt; Neutralizing antibodies for Covid-19 were formed after day 14 and started to increase on day 28 and started to decrease in months 3 and 6. The levels of NAb for Covid-19 were measured with Ichroma and iFlash in roughly the same pattern and had a moderate positive correlation.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">171</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Hartono Kahar&lt;sup&gt;1,*&lt;/sup&gt;, Sari Prabandari Prasetyaningrum&lt;sup&gt;2&lt;/sup&gt;, Munawaroh Fitriah&lt;sup&gt;2&lt;/sup&gt;, Aryati&lt;sup&gt;2&lt;/sup&gt;, Jusak Nugraha&lt;sup&gt;2&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Laboratory Instalation, Dr. Soetomo Hospital, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Clinical Pathology Specialization Program, Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sari Prabandari Prasetyaningrum</style></author><author><style face="normal" font="default" size="100%">Arief Bakhtiar</style></author><author><style face="normal" font="default" size="100%">Yessy Puspitasari</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Correlation of TB LAM Ag (Tuberculosis Lipoarabinomannan Antigen) Results from Urine with Adenosine Deaminase Levels from Pleural Fluid Patients with Pulmonary TB Accompanied by Pleural Effusion</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Active TB with pleural effusion.</style></keyword><keyword><style  face="normal" font="default" size="100%">Adenosine deaminase (ADA) test</style></keyword><keyword><style  face="normal" font="default" size="100%">TB Lipoarabinomannan (LAM) Antigen</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">March 2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">15</style></volume><pages><style face="normal" font="default" size="100%">47-51</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background: &lt;/strong&gt;One of the newest testing methods for active TB uses TB LAM Antigen, in which lipoarabinomannan (LAM) as the examined substance serves as the main component of the cell wall of M. tuberculosis (MTB) and the degradation product of MTB by macrophages in the human body. Patients with active TB with or without HIV infection may experience a decreased antibody response, which causes LAM not to bind to antibodies so that it can pass through the normal glomerular basement membrane and can be detected in the urine. Lateral flow urine lipoarabinomannan assay (LF-LAM) can detect this material with urine samples from active TB patients. Another TB screening method uses the measurement of adenosine deaminase (ADA) activity. ADA has a very important function for the proliferation and differentiation of lymphoid cells, especially T cells, and assists in the maturation of monocytes into macrophages. &lt;strong&gt;Objective&lt;/strong&gt;: This study aims to qualitatively prove the correlation between the pleural fluid ADA levels of pulmonary TB patients with pleural effusion using the LF-LAM test results and examine the potential of TB LAM Ag, which correlates with increased pleural fluid ADA levels, as a diagnostic tool for diagnosing pulmonary TB. &lt;strong&gt;Method:&lt;/strong&gt; It is an observational analytic study with a crosssectional design. Materials for this study included temporary urine from active TB patients at Dr. Soetomo Regional Public Hospital collected in May-August 2022. The descriptive analysis was conducted using SPSS 25.0. The data were tested for normal distribution and with the homogeneity test of Shapiro-Wilk's data. The statistical analysis was performed using the Mann-Whitney test, while the kappa suitability test was carried out to determine the correlation and level of concordance between the ADA cut-off value of pleural fluid and the TB LAM Ag test results. Results: This study involved 50 subjects consisting of 22 (44%) subjects with ADA test results between 40-100 IU/L compared to 28 subjects (56%) with ADA test results below 40 IU/L. There were 14 (28%) subjects with positive TB LAM Ag test results, consisting of 10 (45%) active TB subjects with a high ADA test cut-off of 40-100 IU/L and 4 (14%) active TB subjects with a low ADA test cut-off below 40 IU/L, with a p-value = 0.012. &lt;strong&gt;Conclusions:&lt;/strong&gt; There is a correlation between TB Lipoarabinomannan antigen test results of TB patients with pleural effusion. TB LAM Ag can be detected positive on ADA test results of &amp;lt; 40 IU/L and more positive in active TB patients with high ADA test results of &amp;gt; 40-100 IU/L. Therefore, the TB LAM Ag test is more sensitive than the ADA test. The cut-off value of the ADA test reached 76.4 U/L, and a positive TB LAM was found.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><work-type><style face="normal" font="default" size="100%">Original Article </style></work-type><section><style face="normal" font="default" size="100%">47</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Sari Prabandari Prasetyaningrum&lt;sup&gt;1,*&lt;/sup&gt;, Arief Bakhtiar&lt;sup&gt;2&lt;/sup&gt;, Yessy Puspitasari&lt;sup&gt;3&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Clinical Pathology Specialization Program, Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Laboratory Instalation, Dr. Soetomo Hospital, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Department of Clinical Pathology, Dr. Soetomo Hospital, Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;
</style></auth-address></record></records></xml>